Compounds > 7-o-succinyl macrolactin a
Page last updated: 2024-11-12

7-o-succinyl macrolactin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-O-succinyl macrolactin A: an antibacterial isolated from Bacillus polyfermenticus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10601542
CHEMBL ID485779
MeSH IDM0559445

Synonyms (3)

Synonym
CHEMBL485779
7-o-succinyl macrolactin a
4-[[(3z,5e,8s,9e,11z,14s,16r,17e,19e,24r)-14,16-dihydroxy-24-methyl-2-oxo-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-8-yl]oxy]-4-oxobutanoic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This method is applicable for the pharmacokinetic studies of SMA in rats."( A simple and sensitive HPLC-UV determination of 7-O-succinyl macrolactin A in rat plasma and urine and its application to a pharmacokinetic study.
Jung, JW; Kang, HE; Kang, JS; Kim, CG; Kim, DH; Kim, JM, 2013)		0.65
"  The pharmacokinetic profiles of both MA and SMA were much improved (greater AUC and F values) following intraperitoneal administration than following oral administration due to avoidance of acidic degradation and/or gastrointestinal first-pass extraction."( Pharmacokinetics of macrolactin A and 7-O-succinyl macrolactin A in mice.
Jung, JW; Kang, HE; Kim, DH; Kim, JM; Kwon, MH, 2014)		0.67

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of an in vitro-in vivo extrapolation, our data strongly suggested that MA and SMA are unlikely to cause clinically significant drug-drug interactions mediated via inhibition or induction of most of the CYPs involved in drug metabolism in vivo, except for the inhibition of CYP2C9 by MA."( Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.
Bae, SH; Bae, SK; Kang, JS; Kim, CG; Kim, D; Kim, DH; Kwon, MJ; Oh, E; Park, JB, 2014)		0.64

Bioavailability

ExcerptReferenceRelevance
"  Both MA and SMA had an extremely low oral extent of absolute bioavailability (F)."( Pharmacokinetics of macrolactin A and 7-O-succinyl macrolactin A in mice.
Jung, JW; Kang, HE; Kim, DH; Kim, JM; Kwon, MH, 2014)		0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1082814Antibacterial activity against Ralstonia solanacearum race 1 assessed as growth inhibition at 50 uL at 28 degC for 3 days2012Journal of agricultural and food chemistry, Mar-28, Volume: 60, Issue:12
Production of bacillomycin- and macrolactin-type antibiotics by Bacillus amyloliquefaciens NJN-6 for suppressing soilborne plant pathogens.
AID376565Antibacterial activity against Bacillus subtilis ATCC 6633 at 50 ug/disk by agar diffusion assay2000Journal of natural products, Jul, Volume: 63, Issue:7
New macrolactins from a marine Bacillus sp. Sc026.
AID376567Antibacterial activity against Staphylococcus aureus ATCC 25923 at 50 ug/disk by agar diffusion assay2000Journal of natural products, Jul, Volume: 63, Issue:7
New macrolactins from a marine Bacillus sp. Sc026.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's10 (83.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.76 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lamotrigine
[no description available]		2.08101,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.110arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
macrolactin a
macrolactin A: a 24-membered macrolide; structure in first source		3.680
ConditionIndicatedRelationship StrengthStudiesTrials
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.110
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0810